Search

Gallium Ga-68 gozetotide

[L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)

Cholecystokinin

Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form. … Cholecystokinin, previously called _pancreozymin_, is synthesized and secreted by enteroendocrine cells in the duodenum (the first portion of the small intestine) and leads to the release of bile and digestive

Crizanlizumab

It was developed by Novartis and was granted FDA approval on November 15, 2019.

Epicept NP-1

Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.

Treprostinil

Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.

Selenomethionine

Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans.

Propacetamol

[A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]

Camphor monobromide

Tofersen

[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.

Sacubitril

It was approved by the FDA after being given the status of priority review for on July 7, 2015.